Abstract
We have examined the acute somatomedin (SM) response to growth hormone (GH) therapy in 21 GH deficient children using a placental membrane radioreceptor assay (RRA), which measures a variety of SMs, and a radioimmunoassay (RIA) specific for SM-C and insulin-like growth factor I (IGF-I). RRA and RIA SM determinations were performed on the same acid-chromatographed samples, obtained before initiation of therapy and 13 hr after each of 4 daily injections of GH (0.1 U/kg). The 4 days of GH therapy resulted in an increase in SM levels from 0.39±0.24(SD)U/ml to 1.18±0.62(SD) U/ml determined by RRA and 0.19±0.14(SD)U/ml to 0.82±0.51(SD)U/ml determined by RIA. A single injection of GH resulted in a significant rise in plasma SM levels measured by either RRA or RIA (p<0.001). Subjects who responded poorly to 2 injections of GH also had low SM levels after 4 days and even after 6 weeks of GH therapy.
The RRA resulted in consistently higher values than the RIA, particularly when compared to a pure IGF-I/SM-C standard. SM peptide content determined by RRA and RIA were strongly correlated for individual subjects as well as for the whole group. However, the RRA/RIA ratio among individual subjects varied from 0.85 to 2.50. The marked difference in SM peptide content measured by RRA and RIA and the variability in the RRA/RIA ratio among individual subjects suggests that the IGF-I/SM-C RIA measures only one of a number of GH dependent SM peptides.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kemp, S., Rosenfeld, R., Hintz, R. et al. 421 ACUTE SOMATOMEDIN RESPONSE TO GROWTH HORMONE THERAPY. Pediatr Res 15 (Suppl 4), 510 (1981). https://doi.org/10.1203/00006450-198104001-00432
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-00432